-
平臺(tái)編號(hào)：bio-129807
-
細(xì)胞信息： JVM-13
-
規(guī)格：1×10?cells/T25培養(yǎng)瓶
-
用途：細(xì)胞系
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
人淋巴瘤細(xì)胞JVM-13
細(xì)胞名稱：人淋巴瘤細(xì)胞JVM-13
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級(jí)：1
用途限制：僅供科研3類
培養(yǎng)體系：DMEM(HYCLONE SH30022.01)+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡(jiǎn)介：人淋巴瘤細(xì)胞JVM-13取自60歲男性供體，該細(xì)胞保藏于ATCC
注釋：Part of:LL-100 blood cancer cell line panel.
Part of:Lymphoma Research Foundation Mantle Cell Lymphoma cell bank(LRF MCL cell bank).
Part of:MD Anderson Cell Lines Project.
Doubling time:58 hours(PubMed=25315077);~70 hours(DSMZ).
Transformant:NCBI_TaxID;10376;Epstein-Barr virus(EBV).
Omics:Deep exome analysis.
Omics:Deep RNAseq analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:Transcriptome analysis.
Derived from sampling site:Peripheral blood.
基因突變
HLA信息
Class I
HLA-A A*03:01,02:01
HLA-B B*56:01,15:01
HLA-C C*01:02,03:03
Class II
HLA-DQ DQA1*01:03,01:03
DQB1*06:03,06:03
HLA-DR DRB1*13:01,03:38
STR信息
Amelogenin X,Y
CSF1PO 10,12
D5S818 11
D7S820 9
D13S317 9,11
D16S539 11
TH01 6,7
TPOX 10,11
vWA 16,18
參考文獻(xiàn)
PubMed=28196595;DOI=10.1016/j.ccell.2017.01.005
Li J.,Zhao W.,Akbani R.,Liu W.,Ju Z.,Ling S.,Vellano C.P.,Roebuck P.,Yu Q.,Eterovic A.K.,Byers L.A.,Davies M.A.,Deng W.,Gopal Y.N.V.,Chen G.,von Euw E.M.,Slamon D.J.,Conklin D.,Heymach J.V.,Gazdar A.F.,Minna J.D.,Myers J.N.,Lu Y.,Mills G.B.,Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=29666304;DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V.,Huang S.-J.,Zhang H.,Zhang J.,Bell T.,Zhou S.,Pogue E.,Ding Z.,Lam L.,Westin J.,Davis R.E.,Young K.H.,Medeiros L.J.,Ford R.J.,Nomie K.,Zhang L.,Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin.Cancer Res.24:3967-3980(2018)
PubMed=31160637;DOI=10.1038/s41598-019-44491-x
Quentmeier H.,Pommerenke C.,Dirks W.G.,Eberth S.,Koeppel M.,MacLeod R.A.F.,Nagel S.,Steube K.,Uphoff C.C.,Drexler H.G.
The LL-100 panel:100 cell lines for blood cancer studies.
Sci.Rep.9:8218-8218(2019)
細(xì)胞操作說(shuō)明下載：細(xì)胞操作說(shuō)明
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級(jí)：1
用途限制：僅供科研3類
培養(yǎng)體系：DMEM(HYCLONE SH30022.01)+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡(jiǎn)介：人淋巴瘤細(xì)胞JVM-13取自60歲男性供體，該細(xì)胞保藏于ATCC
注釋：Part of:LL-100 blood cancer cell line panel.
Part of:Lymphoma Research Foundation Mantle Cell Lymphoma cell bank(LRF MCL cell bank).
Part of:MD Anderson Cell Lines Project.
Doubling time:58 hours(PubMed=25315077);~70 hours(DSMZ).
Transformant:NCBI_TaxID;10376;Epstein-Barr virus(EBV).
Omics:Deep exome analysis.
Omics:Deep RNAseq analysis.
Omics:Protein expression by reverse-phase protein arrays.
Omics:Transcriptome analysis.
Derived from sampling site:Peripheral blood.
基因突變
HLA信息
Class I
HLA-A A*03:01,02:01
HLA-B B*56:01,15:01
HLA-C C*01:02,03:03
Class II
HLA-DQ DQA1*01:03,01:03
DQB1*06:03,06:03
HLA-DR DRB1*13:01,03:38
STR信息
Amelogenin X,Y
CSF1PO 10,12
D5S818 11
D7S820 9
D13S317 9,11
D16S539 11
TH01 6,7
TPOX 10,11
vWA 16,18
參考文獻(xiàn)
PubMed=28196595;DOI=10.1016/j.ccell.2017.01.005
Li J.,Zhao W.,Akbani R.,Liu W.,Ju Z.,Ling S.,Vellano C.P.,Roebuck P.,Yu Q.,Eterovic A.K.,Byers L.A.,Davies M.A.,Deng W.,Gopal Y.N.V.,Chen G.,von Euw E.M.,Slamon D.J.,Conklin D.,Heymach J.V.,Gazdar A.F.,Minna J.D.,Myers J.N.,Lu Y.,Mills G.B.,Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=29666304;DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V.,Huang S.-J.,Zhang H.,Zhang J.,Bell T.,Zhou S.,Pogue E.,Ding Z.,Lam L.,Westin J.,Davis R.E.,Young K.H.,Medeiros L.J.,Ford R.J.,Nomie K.,Zhang L.,Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin.Cancer Res.24:3967-3980(2018)
PubMed=31160637;DOI=10.1038/s41598-019-44491-x
Quentmeier H.,Pommerenke C.,Dirks W.G.,Eberth S.,Koeppel M.,MacLeod R.A.F.,Nagel S.,Steube K.,Uphoff C.C.,Drexler H.G.
The LL-100 panel:100 cell lines for blood cancer studies.
Sci.Rep.9:8218-8218(2019)
細(xì)胞操作說(shuō)明下載：細(xì)胞操作說(shuō)明
